Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease

Author(s): Mine Silindir Gunay, A. Yekta Ozer, Sylvie Chalon.

Journal Name: Current Neuropharmacology

Volume 14 , Issue 4 , 2016

Abstract:

Background: Although a variety of therapeutic approaches are available for the treatment of Parkinson’s disease, challenges limit effective therapy. Among these challenges are delivery of drugs through the blood brain barier to the target brain tissue and the side effects observed during long term administration of antiparkinsonian drugs. The use of drug delivery systems such as liposomes, niosomes, micelles, nanoparticles, nanocapsules, gold nanoparticles, microspheres, microcapsules, nanobubbles, microbubbles and dendrimers is being investigated for diagnosis and therapy.

Methods: This review focuses on formulation, development and advantages of nanosized drug delivery systems which can penetrate the central nervous system for the therapy and/or diagnosis of PD, and highlights future nanotechnological approaches.

Results: It is esential to deliver a sufficient amount of either therapeutic or radiocontrast agents to the brain in order to provide the best possible efficacy or imaging without undesired degradation of the agent. Current treatments focus on motor symptoms, but these treatments generally do not deal with modifying the course of Parkinson’s disease. Beyond pharmacological therapy, the identification of abnormal proteins such as α -synuclein, parkin or leucine-rich repeat serine/threonine protein kinase 2 could represent promising alternative targets for molecular imaging and therapy of Parkinson’s disease.

Conclusion: Nanotechnology and nanosized drug delivery systems are being investigated intensely and could have potential effect for Parkinson’s disease. The improvement of drug delivery systems could dramatically enhance the effectiveness of Parkinson’s Disease therapy and reduce its side effects.

Keywords: Advantages of drug delivery systems, drug delivery systems, imaging of Parkinson’s disease, liposomes, microbubbles, nanoparticles, therapy of Parkinson’s disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 4
Year: 2016
Page: [376 - 391]
Pages: 16
DOI: 10.2174/1570159X14666151230124904
Price: $58

Article Metrics

PDF: 34
HTML: 3
EPUB: 1
PRC: 1